Abeona Therapeutics Stock Filter Stocks by Fundamentals
| ABEO Stock | USD 7.93 0.17 2.19% |
Abeona Therapeutics fundamentals help investors to digest information that contributes to Abeona Therapeutics' financial success or failures. It also enables traders to predict the movement of Abeona Stock. The fundamental analysis module provides a way to measure Abeona Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Abeona Therapeutics stock.
Abeona | Shares Owned by Insiders |
Abeona Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Abeona Therapeutics from analyzing Abeona Therapeutics' financial statements. These drivers represent accounts that assess Abeona Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Abeona Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 339.4M | 164.7M | 145.5M | 24.2M | 107.1M | 118.4M | |
| Enterprise Value | 350.6M | 43.4M | 141.6M | 17.6M | 97.7M | 94.4M |
Abeona Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Abeona Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Abeona Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Abeona Therapeutics' value.| Shares | Worth Venture Partners, Llc | 2023-12-31 | 196.4 K | Walleye Trading Advisors, Llc | 2023-12-31 | 188 K | Blackrock Inc | 2023-12-31 | 186.4 K | Renaissance Technologies Corp | 2023-12-31 | 182.4 K | Barclays Plc | 2023-12-31 | 169.7 K | Boothbay Fund Management, Llc | 2023-12-31 | 160.3 K | Schonfeld Strategic Advisors Llc | 2023-09-30 | 153.9 K | Northern Trust Corp | 2023-12-31 | 131.9 K | Eam Investors, Llc | 2023-12-31 | 97.8 K | Nantahala Capital Management, Llc | 2023-12-31 | 4.5 M | Adage Capital Partners Gp Llc | 2023-12-31 | 3.2 M |
Abeona Fundamentals
| Return On Equity | -2.61 | ||||
| Return On Asset | -0.47 | ||||
| Operating Margin | (13.77) % | ||||
| Current Valuation | 165.45 M | ||||
| Shares Outstanding | 27.36 M | ||||
| Shares Owned By Insiders | 4.94 % | ||||
| Shares Owned By Institutions | 59.93 % | ||||
| Number Of Shares Shorted | 1.99 M | ||||
| Price To Earning | 0.11 X | ||||
| Price To Book | 13.93 X | ||||
| Price To Sales | 59.01 X | ||||
| Revenue | 3.5 M | ||||
| Gross Profit | (28 M) | ||||
| EBITDA | (45 M) | ||||
| Net Income | (54.19 M) | ||||
| Cash And Equivalents | 20.1 M | ||||
| Cash Per Share | 3.38 X | ||||
| Total Debt | 5.4 M | ||||
| Debt To Equity | 0.42 % | ||||
| Current Ratio | 2.21 X | ||||
| Book Value Per Share | 0.56 X | ||||
| Cash Flow From Operations | (37.01 M) | ||||
| Short Ratio | 4.63 X | ||||
| Earnings Per Share | (2.53) X | ||||
| Target Price | 21.0 | ||||
| Number Of Employees | 84 | ||||
| Beta | 1.48 | ||||
| Market Capitalization | 212.27 M | ||||
| Total Asset | 64 M | ||||
| Retained Earnings | (749.52 M) | ||||
| Working Capital | 42.31 M | ||||
| Current Asset | 31.95 M | ||||
| Current Liabilities | 6.51 M | ||||
| Net Asset | 64 M |
About Abeona Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Abeona Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Abeona Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Abeona Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Abeona Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Abeona Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Abeona Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Abeona Stock
| 0.57 | LPTX | Leap Therapeutics Financial Report 20th of May 2024 | PairCorr |
The ability to find closely correlated positions to Abeona Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Abeona Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Abeona Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Abeona Therapeutics to buy it.
The correlation of Abeona Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Abeona Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Abeona Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Abeona Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Abeona Therapeutics Piotroski F Score and Abeona Therapeutics Altman Z Score analysis. To learn how to invest in Abeona Stock, please use our How to Invest in Abeona Therapeutics guide.Note that the Abeona Therapeutics information on this page should be used as a complementary analysis to other Abeona Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Complementary Tools for Abeona Stock analysis
When running Abeona Therapeutics' price analysis, check to measure Abeona Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Abeona Therapeutics is operating at the current time. Most of Abeona Therapeutics' value examination focuses on studying past and present price action to predict the probability of Abeona Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Abeona Therapeutics' price. Additionally, you may evaluate how the addition of Abeona Therapeutics to your portfolios can decrease your overall portfolio volatility.
| CEOs Directory Screen CEOs from public companies around the world | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |
Is Abeona Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abeona Therapeutics. If investors know Abeona will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abeona Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.53) | Revenue Per Share 0.164 | Quarterly Revenue Growth (1.00) | Return On Assets (0.47) | Return On Equity (2.61) |
The market value of Abeona Therapeutics is measured differently than its book value, which is the value of Abeona that is recorded on the company's balance sheet. Investors also form their own opinion of Abeona Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Abeona Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abeona Therapeutics' market value can be influenced by many factors that don't directly affect Abeona Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Abeona Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Abeona Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abeona Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.